Image Source: Eenadu
Sequent Scientific has taken a major leap forward in its growth journey, securing crucial approvals from both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) for its high-profile merger with Viyash Life Sciences. This green light marks a pivotal milestone in the creation of a global, end-to-end animal health and pharmaceutical platform.
Key Milestones
-
The merger, valued at approximately Rs 8,000 crore, will see Viyash shareholders receive 56 Sequent shares for every 100 Viyash shares, with Sequent remaining the surviving listed entity. The new shares will be traded on both NSE and BSE once the scheme becomes effective.
-
This strategic union is designed to build a differentiated, integrated platform with leadership in animal pharmaceuticals, leveraging a robust R&D backbone and a strengthened global supply chain.
-
The combined entity will boast 16 manufacturing plants, including 10 USFDA-approved facilities, and a significantly expanded R&D team—six times larger than before. This scale-up will enable five times higher manufacturing capacity and eight times more new product filings.
-
Financially, the merger aims to turbocharge growth: the combined Q4 FY25 proforma revenues reached Rs 7,725 million, up 13.2% year-on-year, with a 63.2% jump in adjusted EBITDA to Rs 1,222 million.
The merger is expected to drive operational synergies, backward integration, and a broader global market reach, positioning Sequent as a leader not only in animal health but also in human healthcare APIs and formulations.
Leadership at both companies hailed the merger as transformative, emphasizing a shared commitment to innovation, operational excellence, and delivering high-quality solutions to customers worldwide.
With regulatory approvals in place, Sequent Scientific and Viyash Life Sciences are poised to set new benchmarks in the global pharmaceuticals industry, accelerating their Sequent 3.0 journey and solidifying their market leadership.
Sources: Moneycontrol, Economic Times, Business Standard, The Hindu BusinessLine, Sequent Scientific Press Release
Advertisement
Advertisement
